Video
9 Sep 2021

Webinar - Tomorrow’s medicines with today’s drug substances

Developing new pharmaceutical products is difficult in today’s environment. Products based on new chemical entities (NCEs) have the potential to generate huge profits, but the development process is long (often 10 years), costs are high (about $ 1 billion) and the risk of failure is great. In contrast, the development of generics is faster and much less costly. However, profits are generally small with a decreasing trend due to fierce competition. An interesting segment is new products using new dosage forms and existing active pharmaceutical ingredients (APIs) - known as “drug delivery innovation.’ Such products offer an alternative as development timelines are shorter, costs are significantly less, and a certain degree of market exclusivity can be gained. Consequently, these products can be highly profitable.

Content provided by our supplier

Recipharm AB

  • SE
  • 2015
    On CPHI since
  • 5000+
    Employees
Company types
Contract Service
Manufacturer/Innovator

Other Content from Recipharm AB (78)